Skip to content
Parakho

Aarti Drugs Ltd

NSE AARTIDRUGSBSE 524348

Q1 FY27

Revenue
₹627.45 Cr
Profit after tax
₹50.85 Cr

As filed with the exchange, standalone basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, standalone basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations627.45+20.44%2,260.39
Other income0.20−47.37%2.59
Total income627.65+20.39%2,262.98
Employee benefit expense26.34+13.10%96.27
Finance costs6.95+1.91%26.38
Depreciation & amortisation15.21+23.96%55.64
Total expenses557.71+17.14%2,081.67
Profit before tax67.85+49.94%181.31
Tax expense17.00+601.47%12.09
Profit after tax50.85+4.54%169.22
Total comprehensive income50.85+4.54%171.69
Earnings per share
Earnings per share, basic₹5.57₹18.54
Earnings per share, diluted₹5.57₹18.54

Q1 FY27 — from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — from the company’s filing with NSE. Source

FY26 — from the company’s filing with NSE. Source

Earnings call

Q1 FY27

Aarti Drugs reported Q1 FY27 consolidated revenue of Rs 703.6 crores, up 19% year-on-year, with EBITDA growing 30% to Rs 96.9 crores and EBITDA margin at 13.8%. Management attributed the growth to improved API realizations amid geopolitical disruptions in West Asia along with steady volume growth across API and Specialty Chemicals segments. The company also discussed progress on its Sayakha facility ramp-up, Metformin capacity expansion plans, and regulatory approvals across its API and formulations businesses.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote. Read the cited summary

Earlier calls: Q4 FY26 · All quarters

Filings

12 shown · 40 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Page generated from filings held to 24 Aug 2026.